Pharmalys at the Epicentre Scientific Day 2025, Institut Pasteur, Paris

Oct 16, 2025 | Quality & Business Excellence

In early June, Pharmalys took part in the Epicentre Scientific Day hosted at the Institut Pasteur in Paris. Representing the company, Business Development and Strategic Partnerships Associate Arthur joined researchers, NGOs, and health professionals to engage with the latest operational research driving impact in global health.

The Epicentre Scientific Day is a long-standing annual event that showcases research conducted in collaboration with Médecins Sans Frontières (MSF) and other partners. This year’s programme featured studies from across Africa, the Middle East, and beyond, covering urgent topics such as cancer care, tuberculosis, infectious disease outbreaks, malnutrition, and antimicrobial resistance.

Discussions from the day underscored the operational challenges and innovations shaping healthcare delivery in resource-limited settings
  • Cancer: Data from Malawi, Mali, and Uganda emphasised the need for early detection and tailored care strategies to improve survival rates.
  • Tuberculosis: Advances in diagnostics and treatment regimens highlighted progress, while post-TB complications remain a critical concern.
  • Outbreaks: Case studies from Nigeria and the DRC reinforced the importance of adaptive response strategies and genetic surveillance, particularly with the emergence of new Mpox variants.
  • Cholera, malaria, and malnutrition: Research pointed to the benefits of rapid diagnostics, surveillance tools, and evolving clinical practices to improve outcomes in fragile settings.
  • Diagnostics & antibiotics: Studies from Zimbabwe and Liberia demonstrated how improved diagnostic capacity can strengthen antimicrobial stewardship and patient care.
Pharmalys’ Participation

Pharmalys was grateful to be part of the year’s Epicentre Scientific Day, which brought together leading voices in global health and humanitarian research. The event offered an invaluable opportunity to listen, learn, and engage with the latest evidence shaping health interventions in complex field settings.

Having previously collaborated with Epicentre on the DeTACT project, Pharmalys was grateful to reconnect and witness firsthand the depth of research driving meaningful impact in communities worldwide, while also exploring new partnerships. Arthur noted his appreciation of the chance to join these conversations and discuss our shared commitment to advancing healthcare delivery in challenging contexts.

This commitment extends beyond research to Pharmalys’ broader Corporate Social Responsibility initiatives, which align with several UN Sustainable Development Goals. Through programmes such as the Pharmalys Academy of Clinical research Excellence (PACE), mentorship of aspiring young female scientists, strategic partnerships with the Mastercard Foundation, and support for free healthcare campaigns in underserved regions, Pharmalys actively invests in strengthening clinical research capacity, creating meaningful employment, and expanding access to essential healthcare services. These initiatives reflect our mission to build a more inclusive, skilled, and resilient research and healthcare environment, reinforcing the values that we share with global health partners such as Epicentre, MSF, and Institut Pasteur de Paris.

The 2025 Epicentre Scientific Day underscored the essential role of operational research in informing policies, improving care, and saving lives in humanitarian and low-resource environments. Pharmalys extends sincere thanks to Epicentre, Institut Pasteur de Paris, and Médecins Sans Frontières for convening this important gathering and for the opportunity to participate.

Watch the full recording of the day’s sessions here.

Ethiopia Reaches WHO Maturity Level 3

Ethiopia Reaches WHO Maturity Level 3

On 3 October 2025, Dr Mekdes Daba, Health Minister of Ethiopia, announced a major achievement for the country: the formal recognition of the Ethiopian Food and Drug Authority (EFDA) as a Maturity Level 3 (ML3) regulatory system by the World Health Organization (WHO)....

Breast Cancer Awareness 2025: Access and Awareness Saves Lives

Breast Cancer Awareness 2025: Access and Awareness Saves Lives

Breast cancer remains the most common cancer among women worldwide. In the United States, statistics suggest that one in eight women will receive a diagnosis in her lifetime. In 2025 alone, it is estimated that 316,950 women and 2,800 men will be diagnosed with...

A Breakthrough in Malaria Care for the Youngest Patients

A Breakthrough in Malaria Care for the Youngest Patients

It’s a sobering truth: malaria still claims the lives of hundreds of thousands of children every year, with the youngest being most at risk. Until now, doctors treating newborns and very small infants under 5 kg faced a dilemma - no treatment had ever been designed...

The Microbiome and Cancer: What Do We Know?

The Microbiome and Cancer: What Do We Know?

Insights from research and an interview with Dr Jennifer Wargo, MD, University of Texas M.D. Anderson Cancer Center, as featured in a recent JAMA interview. The human body is home to trillions of microbes - bacteria, viruses, fungi, and other microorganisms - that...